A healthy lifestyle in early childhood is associated with a reduced risk for inflammatory bowel disease (IBD), according to a study published online August 24 i ...

Lisraya is the first oral dual TYK2/JAK1 inhibitor indicated for adults with dermatomyositis, demonstrating significant ...

The updated vaccines are expected to be available in pharmacies, hospitals, and clinics in the coming days. In May 2026, the FDA’s Vaccines and Related Biological Products Advisory Committee ...

HealthDay News — Baseline cortical atrophy measured within the early-onset Alzheimer disease (EOAD) signature, a set of predominantly parietotemporal regions showing greater atrophy in EOAD than in ...

Interim Phase 1b/2a trial data support the MKK4 inhibitor's potential to protect hepatocytes and accelerate liver regeneration following surgical resection.

The FDA expanded tirzepatide's indication to include major adverse cardiovascular event reduction in adults with type 2 diabetes and established CV risk.

Imaavy (nipocalimab-aahu) is the first FcRn blocker approved to treat warm autoimmune hemolytic anemia in patients aged 12 years and older.

Bixlenvo demonstrated noninferiority to multi-tablet and 3-drug regimens in virologically suppressed adults with HIV-1, expanding single-tablet options for patients on complex regimens. The Food and ...

HealthDay News — Paternal exposure to valproate during sperm development is not associated with neurodevelopmental disorders (NDDs) in offspring, according to a study published online August 19 in ...

The FDA has approved Tivicay PD dispersible tablets for combination HIV-1 treatment in full-term neonates weighing at least 2kg.